Although administering trastuzumab to early and metastatic HER2+ breast cancer patients along with other chemotherapeutic treatments improves their survival by 50%, patients often develop early cardiomyopathy which can later progress to ventricular dysfunction succeeding treatment completion (Portera et al., 2008). This evidence concerns the gene ERBB2 and breast cancer.